EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

[News]

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.

More... (http://www.news-medical.net/news/20150819/EnGeneIC-begins-Phase-1-Tailored-EDV-trial-for-advanced-solid-tumor.aspx)